Cargando…
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063815/ https://www.ncbi.nlm.nih.gov/pubmed/32175074 http://dx.doi.org/10.1186/s13578-020-00396-1 |
_version_ | 1783504765681926144 |
---|---|
author | Zou, Zhilin Tao, Tao Li, Hongmei Zhu, Xiao |
author_facet | Zou, Zhilin Tao, Tao Li, Hongmei Zhu, Xiao |
author_sort | Zou, Zhilin |
collection | PubMed |
description | Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases. The mTOR signaling pathway, which is often activated in tumors, not only regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation but also plays an important role in tumor metabolism. Therefore, the mTOR signaling pathway is a hot target in anti-tumor therapy research. In recent years, a variety of newly discovered mTOR inhibitors have entered clinical studies, and a variety of drugs have been proven to have high activity in combination with mTOR inhibitors. The purpose of this review is to introduce the role of mTOR signaling pathway on apoptosis, autophagy, growth, and metabolism of tumor cells, and to introduce the research progress of mTOR inhibitors in the tumor field. |
format | Online Article Text |
id | pubmed-7063815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70638152020-03-13 mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges Zou, Zhilin Tao, Tao Li, Hongmei Zhu, Xiao Cell Biosci Review Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases. The mTOR signaling pathway, which is often activated in tumors, not only regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation but also plays an important role in tumor metabolism. Therefore, the mTOR signaling pathway is a hot target in anti-tumor therapy research. In recent years, a variety of newly discovered mTOR inhibitors have entered clinical studies, and a variety of drugs have been proven to have high activity in combination with mTOR inhibitors. The purpose of this review is to introduce the role of mTOR signaling pathway on apoptosis, autophagy, growth, and metabolism of tumor cells, and to introduce the research progress of mTOR inhibitors in the tumor field. BioMed Central 2020-03-10 /pmc/articles/PMC7063815/ /pubmed/32175074 http://dx.doi.org/10.1186/s13578-020-00396-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zou, Zhilin Tao, Tao Li, Hongmei Zhu, Xiao mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title_full | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title_fullStr | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title_full_unstemmed | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title_short | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges |
title_sort | mtor signaling pathway and mtor inhibitors in cancer: progress and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063815/ https://www.ncbi.nlm.nih.gov/pubmed/32175074 http://dx.doi.org/10.1186/s13578-020-00396-1 |
work_keys_str_mv | AT zouzhilin mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges AT taotao mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges AT lihongmei mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges AT zhuxiao mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges |